Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cann Group ( (AU:CAN) ) just unveiled an update.
Cann Group Limited has resolved its legal dispute with Rua Biosciences Limited by entering into a confidential deed of settlement and release, which includes mutual release from claims and two commercial agreements for Cann to supply medicinal cannabis products to Rua for distribution in Australia and New Zealand. This settlement not only resolves the dispute but also establishes a new commercial relationship between the two companies, potentially impacting their operations and market positioning positively.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. It operates research facilities and a large-scale cultivation and GMP manufacturing facility in Victoria, Australia. The company supplies dried flower and oil products, active pharmaceutical ingredients, and extracts to customers globally, and owns Satipharm with its patent-protected capsule technology.
Average Trading Volume: 1,799,039
Technical Sentiment Signal: Sell
Current Market Cap: A$8.09M
For detailed information about CAN stock, go to TipRanks’ Stock Analysis page.